Skip to navigation Skip to content

Clinical Trial: N-Acetyl Cysteine

Share

Details
Type of MS: PPMS|RRMS|SPMS
Treatment mode of action: To improve metabolic activity in the brain
Number of Subjects: 30
Medication: N-Acetyl Cysteine
Location: Pennsylvania
Institutions: Thomas Jefferson University
Philadelphia, Pennsylvania Contact Information
Nancy Wintering, LCSW, CCRP
(215) 503-3423
nancy.wintering@jefferson.edu

Funding:

Thomas Jefferson University

Description

The study consists of two arms. The first arm of this study will receive intravenous and oral NAC, a strong antioxidant that increases brain glutathione. NAC, is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. It has the potential to increase glutathione in blood, which might be useful in preventing oxidative damage in MS patients. The second arm will be a waitlist control receiving standard MS care. It should be noted that both arms will receive standard of care treatment for MS while enrolled in the study.

Share